Navigation Links
Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
Date:2/26/2008

to the placebo group (28%; p=0.0276). Overall survival improvement trends were consistently observed across subsets of patients grouped by major prognostic factors, including disease stage, performance status, and line of therapy. Positive trends were also observed on the secondary endpoints including progression-free survival (PFS) and disease control rate.

In addition to the efficacy improvements, oral talactoferrin was well tolerated in this group of patients with previously treated NSCLC. Adverse events (AEs) were generally mild, and no drug-related serious AEs were reported. There were 26% fewer AEs and 48% fewer Grade 3/4/5 AEs in the talactoferrin group relative to the placebo group (p=0.0037 and p=0.0024, respectively).

"These exciting data hold promise for the historic battle being conducted to find effective treatments for the most lethal forms of cancer," said Dr. Peter Traber, President of Baylor College of Medicine, where talactoferrin was first produced in the laboratory. "It is our sincere hope that the Phase 3 trials of talactoferrin will be successful and this drug can eventually be used globally."

About the Phase 3 NSCLC Monotherapy Study

Building on the results of the two positive Phase 2 studies, preparations are underway for Phase 3 trials with talactoferrin in two NSCLC indications: (i) first-line in combination with chemotherapy, and (ii) monotherapy in patients who have failed two or more previous therapies.

The pivotal Phase 3, multinational, randomized, double-blind, placebo- controlled monotherapy study will enroll 720 patients with Stage IIIB or IV NSCLC who have failed two or more previous therapies. Patients will receive standard supportive care and be randomly assigned (2:1) to receive single- agent treatment with either oral talactoferrin or placebo until disease progression. Overall survival will be the primary endpoint for approval. Secondary endpoints include adverse event reductions, progression
'/>"/>

SOURCE Agennix
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
2. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
3. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
4. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
5. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
6. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
7. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
8. Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior
9. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
10. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
11. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Calif. , July 28, 2014  Isis Pharmaceuticals, ... webcast:What:Isis Pharmaceuticals, Second Quarter 2014 Financial Results and Highlights ... 7:30 a.m. PTWhere: www.isispharm.com How:Live on the Internet. ... are unable to participate during the live event, a ... limited time at www.isispharm.com . ABOUT ...
(Date:7/28/2014)... , July 28, 2014 CTI BioPharma Corp. ... will report its second quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
(Date:7/25/2014)... , July 25, 2014  In today,s marketplace, ... costly and challenging - as is managing a portfolio ... Is it possible - or even preferable - ... so, where can you combine resources and activities, and ... These are just a few of the ...
Breaking Medicine Technology:Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... DIA and the National Pharmaceutical Council (NPC) ... User,s Guide  Conference on March 14-15 at the ... will focus on the continued push for increased ... applied within health technology assessments, research planning and ...
... 2012 PhotoVoltaic Solar Cells, Inc. (OTCBB: PVSO) ... February 27, 2012, it completed a share exchange ... focused on developing and commercializing proprietary clinical diagnostic ... as well as companion therapeutics to prevent systemic ...
Cached Medicine Technology:DIA and National Pharmaceutical Council Will Host Two-Day Conference on Comparative Effectiveness Research 2PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc. 2PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc. 3PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc. 4
(Date:7/28/2014)... into improving treatment for patients with one of the ... funding boost. , Chronic obstructive pulmonary disease (COPD) is ... breathing difficulties due to long-term damage to the lungs. ... 10 per cent of all hospital admissions in the ... to hospital after they are discharged. , ...
(Date:7/28/2014)... The report “Industrial Enzymes Market by Types (Carbohydrase, ... Bio-Fuel, Animal Feed), & Geography - Global Trends ... global industrial enzymes market with analysis and forecasting ... also identifies driving and restraining factors for the ... opportunities, burning issues, winning imperatives, and challenges. The ...
(Date:7/28/2014)... 28, 2014 The Wireline Services Market in ... Europe with analysis and forecast of revenue. The Wireline services ... billion in 2013 to $2.4 billion by 2019, at a ... the TOC of the Wireline Services Market in Europe report, ... also provides a glimpse of the segmentation in the European ...
(Date:7/28/2014)... 2014 (HealthDay News) -- People with higher levels of ... diabetes, a new study suggests. Unlike white fat, ... actually improves insulin sensitivity, blood sugar control and fat-burning ... obese people," Labros Sidossis, a professor of internal medicine ... of Texas Medical Branch at Galveston, said in ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 In response ... Americans face today, BlogHer, The Center for American Progress ... “Make Life Work,” a campaign to raise awareness and ... across the U.S. The joint initiative was announced on ... Editor-in-Chief, BlogHer; Judith Warner, Senior Fellow, The Center for ...
Breaking Medicine News(10 mins):Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Healthy 'Brown Fat' May Cut Odds for Obesity, Diabetes 2Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 2Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 3Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 4Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 5
... DALLAS and PLANO, Texas, March 1 Skin damage. If,you ... about you -- about,your time as a smoker (lip lines), ... age spots), or perhaps you,re,seeing a little more of Mom ... Yes, part of what you,re seeing is normal skin aging, ...
... The California,Academy of Physician Assistants (CAPA) announced that physician ... Speaker of the,California State Assembly. Bass, a member of ... former faculty member at the,University of Southern California School ... Assembly in 2004., As a physician assistant (PA), ...
... 29, 2008 A new study led by researchers at ... that can enhance the function of a protein that is ... protein, called AML1, plays a critical role in the development ... and immune cells. The findings are published in the March ...
... to be unveiled at the 2008 Orthopedic Research ... Society meeting in San Francisco, ... collaboration with RUSH University in Chicago, announces significant,findings that wear ... accelerated aging. The study, "The Effect,of Accelerated Aging on the ...
... Separate Medical ... Businesses, BATESVILLE, Ind., Feb. 29 Hillenbrand,Industries, Inc. (NYSE: ... a cash tender offer to purchase any and all of ... of which $250,million in aggregate principal amount was outstanding as ...
... small striped fish is helping scientists understand what makes people ... this case, its not the fishs ears that are of ... of the journal PLoS Genetics, researchers at the University of ... zebrafishs lateral linethe faint line running down each side of ...
Cached Medicine News:Health News:The DOT CO2 Fractional: The Next Step in Laser Skin Resurfacing 2Health News:The DOT CO2 Fractional: The Next Step in Laser Skin Resurfacing 3Health News:The DOT CO2 Fractional: The Next Step in Laser Skin Resurfacing 4Health News:Physician Assistant Karen Bass Elected Speaker Elect of California State Assembly 2Health News:Novel mechanism found that may boost impaired function of leukemia protein 2Health News:Pioneer(R) Surgical Technology, Inc. Continues to Prove Science Behind PEEK-on-PEEK(TM) Technology for Motion Preservation Devices 2Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 4Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 5Health News:Zebrafish provide useful screening tool for genes, drugs that protect against hearing loss 2Health News:Zebrafish provide useful screening tool for genes, drugs that protect against hearing loss 3
... from Thermo Labsystems was designed specifically to ... features such as the new fast dial ... microvolumes help to define this as a ... new interchangeable handle plate offers a custom ...
Research® Series 2100 Adjustable-volume Pipette, 0.5-10 µl, single-channel with adjustable-volume setting...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,412-7) or contact custom...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... features: Eppendorf "pipette/tip" system ensures utmost ...
Medicine Products: